GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Hybio Pharmaceutical Co Ltd (SZSE:300199) » Definitions » Cyclically Adjusted Revenue per Share

Hybio Pharmaceutical Co (SZSE:300199) Cyclically Adjusted Revenue per Share : ¥0.91 (As of Mar. 2024)


View and export this data going back to 2011. Start your Free Trial

What is Hybio Pharmaceutical Co Cyclically Adjusted Revenue per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Hybio Pharmaceutical Co's adjusted revenue per share for the three months ended in Mar. 2024 was ¥0.213. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is ¥0.91 for the trailing ten years ended in Mar. 2024.

During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 4.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Hybio Pharmaceutical Co was 7.20% per year. The lowest was 4.40% per year. And the median was 5.80% per year.

As of today (2024-05-05), Hybio Pharmaceutical Co's current stock price is ¥12.88. Hybio Pharmaceutical Co's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 was ¥0.91. Hybio Pharmaceutical Co's Cyclically Adjusted PS Ratio of today is 14.15.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Hybio Pharmaceutical Co was 25.82. The lowest was 5.44. And the median was 11.23.


Hybio Pharmaceutical Co Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for Hybio Pharmaceutical Co's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hybio Pharmaceutical Co Cyclically Adjusted Revenue per Share Chart

Hybio Pharmaceutical Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.73 0.79 0.83 0.90 0.90

Hybio Pharmaceutical Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.91 0.91 0.92 0.90 0.91

Competitive Comparison of Hybio Pharmaceutical Co's Cyclically Adjusted Revenue per Share

For the Drug Manufacturers - Specialty & Generic subindustry, Hybio Pharmaceutical Co's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Hybio Pharmaceutical Co's Cyclically Adjusted PS Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Hybio Pharmaceutical Co's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Hybio Pharmaceutical Co's Cyclically Adjusted PS Ratio falls into.



Hybio Pharmaceutical Co Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Hybio Pharmaceutical Co's adjusted Revenue per Share data for the three months ended in Mar. 2024 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=0.213/114.6694*114.6694
=0.213

Current CPI (Mar. 2024) = 114.6694.

Hybio Pharmaceutical Co Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201406 0.109 98.200 0.127
201409 0.137 98.900 0.159
201412 0.137 99.000 0.159
201503 0.138 99.900 0.158
201506 0.157 99.500 0.181
201509 0.227 100.500 0.259
201512 0.318 100.600 0.362
201603 0.188 102.200 0.211
201606 0.184 101.400 0.208
201609 0.295 102.400 0.330
201612 0.272 102.600 0.304
201703 0.224 103.200 0.249
201706 0.282 103.100 0.314
201709 0.254 104.100 0.280
201712 0.556 104.500 0.610
201803 0.293 105.300 0.319
201806 0.417 104.900 0.456
201809 0.277 106.600 0.298
201812 0.386 106.500 0.416
201903 0.210 107.700 0.224
201906 0.258 107.700 0.275
201909 0.115 109.800 0.120
201912 0.056 111.200 0.058
202003 0.210 112.300 0.214
202006 0.256 110.400 0.266
202009 0.281 111.700 0.288
202012 0.038 111.500 0.039
202103 0.228 112.662 0.232
202106 0.189 111.769 0.194
202109 0.149 112.215 0.152
202112 0.165 113.108 0.167
202203 0.174 114.335 0.175
202206 0.229 114.558 0.229
202209 0.181 115.339 0.180
202212 0.223 115.116 0.222
202303 0.189 115.116 0.188
202306 0.192 114.558 0.192
202309 0.076 115.339 0.076
202312 0.036 114.669 0.036
202403 0.213 114.669 0.213

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


Hybio Pharmaceutical Co  (SZSE:300199) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Hybio Pharmaceutical Co's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=12.88/0.91
=14.15

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Hybio Pharmaceutical Co was 25.82. The lowest was 5.44. And the median was 11.23.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Hybio Pharmaceutical Co Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of Hybio Pharmaceutical Co's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Hybio Pharmaceutical Co (SZSE:300199) Business Description

Traded in Other Exchanges
N/A
Address
4th Floor, Office Building, Hanyu Biomedical Park, Middle District, High-tech Industrial Park, Nanshan District, Guangdong Province, Shenzhen, CHN, 518057
Hybio Pharmaceutical Co Ltd is engaged in manufacturing and sale of peptide products. The company's peptide finished dosage products include digestive system agents, immune modulators, hormone and endocrine modulators, antiviral agents, and hemostatic products. It also provides peptide CRO and CMO services, as well as API products.

Hybio Pharmaceutical Co (SZSE:300199) Headlines

No Headlines